4 recruiting, 3 not yet recruiting. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Not yet recruiting 3 |
Follow Culmerciclib: new trials by email Literature Review of Culmerciclib trials Research Report on Culmerciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positiveļ¼ Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Culmerciclib, Aromatase Inhibitor (AI) - Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-09-14 | 2026-09-15 |
| Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer Culmerciclib, Letrozole, Trastuzumab (TQB211) - Breast Cancer, HR Positive, HER2 Positive Breast Cancer | Phase 2 | Not yet recruiting | Shengjing Hospital | 33 | 2026-09-01 | 2026-08-31 |
| Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 31 | 2026-09-01 | 2026-10-19 |
| Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases Culmerciclib, Anlotinib, Endocrine Therapy - HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2026-08-28 | 2026-08-04 |
| Culmerciclib in HR+/HER2+ Advanced Breast Cancer Culmerciclib - Breast Cancer, Metastastic Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 35 | 2026-08-01 | 2026-07-29 |
| A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy. CDK4/6 inhibitor, Culmerciclib, Fulvestrant - Breast Cancer | Phase 2 | Recruiting | Fudan University | 98 | 2026-06-06 | 2026-06-24 |
| Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer Culmerciclib, Aromatase Inhibitors - HR+/HER2- Early Breast Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-05-06 | 2026-06-01 |
Breast Neoplasms (5)
Sun Yat-sen University (2) · Fudan University (1) · Hebei Medical University Fourth Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shengjing Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
China (6)
Chang Gong (1) · Cuizhi Geng, MD (1) · Shusen Wang, MD (1) · Yiding Chen (1)
PMID 16622270, PMID 18997125, PMID 24529560, PMID 26297356, PMID 28135148, PMID 30307466, PMID 31838010, PMID 32330069, PMID 33507815, PMID 34902335, PMID 35020204, PMID 35337692, PMID 36821125, PMID 38751537, PMID 41413016